What Guerbet does

Guerbet SA is a France-headquartered (Villepinte) pharmaceutical and medical device company founded in 1926 by André Guerbet and listed on Euronext Paris compartment B (ticker: GBT). The company's heritage traces to Marcel Guerbet's 1901 discovery of Lipiodol, the world's first iodinated contrast agent. Guerbet develops, manufactures, and commercializes contrast media (iodinated agents for X-ray/CT, gadolinium-based agents for MRI), injection systems (OptiStar Elite, OptiOne, OptiVantage, Illumena Néo), and interventional radiology devices (Lipiodol Ultra Fluid, Vectorio mixing system, SeQure and DraKon microcatheters, Qitexio) for hospitals, diagnostic imaging centers, and interventional radiology departments. The group operates manufacturing facilities in France (Aulnay-sous-Bois, Lanester), the United States (Raleigh, NC and Dublin), and Brazil (Rio de Janeiro), with R&D centers in France and the United States spending approximately 9% of revenue on research.

Guerbet generates revenue through three business lines: Diagnostic Imaging (the largest segment, including MRI agents such as Dotarem and Elucirem, CT/X-ray agents such as Xenetix, Optiray, and Conray, and associated injectors and consumables), Interventional Imaging (Lipiodol Ultra Fluid, Patent Blue V, and microcatheter/mixing devices), and Digital & AI Solutions (icobrain, Contrast & Care, UNIK platform, and Intrasense-developed DUOnco Pancreas). Distribution combines direct sales via local subsidiaries in 20+ countries with distributor networks in Latin America, Europe, and Asia; 85% of revenue is generated outside France.

FY2025 revenue was EUR 786.4 million (down 3.5% like-for-like) and the group posted a EUR 112.7 million net loss including a EUR 86 million impairment tied to an FDA compliance plan at the Raleigh, NC manufacturing site. Q1 2026 revenue returned to growth at +2.6% like-for-like (EMEA +4.5%), and the group secured recent regulatory milestones including the April 2026 EU worksharing approval for Lipiodol Ultra Fluid in vascular embolization, a February 2026 FDA pediatric label expansion for Elucirem, and January 2026 PMDA certification in Japan for DUOnco Pancreas. Leadership is in transition, with Antoine Fady appointed as future Chairman in March 2026.

Name

Guerbet

Legal name

Guerbet SA

Website

https://guerbet.com

Company type

Public

Founded year

1926

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Guerbet is a French pharmaceutical and medical device company founded in 1926 that develops contrast agents, injectors, microcatheters, and AI diagnostic software for hospitals, diagnostic imaging centers, and interventional radiologists across 20+ countries.

Ownership category

akta.pro rank

Product category

Medical Imaging Contrast Media and Interventional Radiology Products

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Contrast Media Injectors & Radiology Accessories (HLAHABAK)

Keywords

• Medical imaging contrast agents
• Diagnostic imaging solutions
• Interventional radiology products
• MRI contrast media
• Pharmaceutical imaging agents

Headquarters

HQ city

Villepinte

HQ country

France

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Imaging: Comprises the largest share of revenue. Includes iodinated contrast agents for X-ray and CT imaging (Xenetix, Optiray, Henetix, Conray, Micropaque, Telebrix, MD-Gastroview), and gadolinium-based contrast agents for MRI (Dotarem, Elucirem, Artirem). Also includes contrast injectors and accessories (OptiStar Elite, OptiVantage, Ready-Box, OptiOne, OptiBolus).
2. Interventional Imaging: Pharmaceutical drugs (Lipiodol Ultra Fluid, Patent Blue V) and medical devices (Vectorio mixing system, SeQure and DraKon micro catheters, Illumena Neo) for interventional radiology procedures including chemoembolization, vascular embolization, and lymphatic mapping.
3. Digital and AI Solutions: Digital solutions including icobrain AI software for radiology, UNIK diagnostic imaging interconnected solutions platform, and AI-augmented diagnosis support tools developed with IBM Watson Health. Represents a strategic initiative for new business development.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Guerbet develops, manufactures, and commercializes medical imaging contrast agents (iodinated agents for X-ray/CT and gadolinium-based agents for MRI), contrast injectors and accessories, interventional radiology pharmaceuticals and medical devices (microcatheters, embolization systems), and digital/AI solutions for diagnostic and interventional imaging. The company's portfolio spans diagnostic imaging, interventional radiology, and women's health, sold primarily to hospitals, diagnostic imaging centers, and radiology departments globally.

Product overview

Guerbet is a global leader in medical imaging offering a comprehensive portfolio of pharmaceutical products, medical devices, and digital/AI solutions for diagnostic and interventional imaging. The product portfolio spans three main categories: (1) Diagnostic Imaging including MRI contrast agents (Dotarem®, Elucirem™/Gadopiclenol, Artirem®) with associated injectors (OptiStar® Elite) and accessories; CT/X-ray contrast agents (Xenetix®, Optiray®, Conray®, Micropaque®, Telebrix®) with injectors (OptiOne™, OptiVantage™) and accessories; and digital solutions (icobrain, Contrast & Care®); (2) Interventional Imaging including pharmaceutical drugs (Lipiodol® Ultra Fluid) and medical devices (Vectorio®, SeQure®, DraKon™ microcatheters, Qitexio®); and (3) Women's Health (Patent Blue V). Products are distributed through the UNIK interconnected solutions platform combining contrast agents, injectors, digital solutions, and services. Guerbet operates in MRI, CT, X-ray, catheter lab/hemodynamics, and interventional radiology segments.

Differentiator

Problem solved

Functional benefit

Brands

• Elucirem™ (Gadopiclenol): Gadolinium-based contrast agent (GBCA) approved at half the conventional dose (0.05 mmol/kg) with the highest relaxivity among available agents, for MRI procedures.
• Lipiodol® Ultra Fluid
• SeQure®
• DraKon™
• Vectorio®
• Dotarem®
• OptiStar® Elite
• UNIK
• Contrast & Care®
• Intrasense

Products and services

• Dotarem Gadolinium-based macrocyclic MRI contrast agent for diagnostic imaging. FDA-approved and available in major markets, used for MRI procedures to detect and visualize lesions.
• Elucirem (Gadopiclenol) Next-generation gadolinium-based contrast agent with the highest relaxivity among available agents, approved at half the conventional dose (0.05 mmol/kg) to reduce cumulative gadolinium exposure. FDA approved for pediatric use including neonates.
• Artirem Gadolinium-based MRI contrast agent formulation offered as part of the MRI product portfolio for diagnostic imaging.
• OptiStar Elite Advanced MRI contrast injection system with enhanced safety and workflow features for automated contrast delivery during MRI procedures.
• Xenetix / ScanBag by Xenetix
• Optiray
• Conray / Cysto-Conray
• Micropaque / Microtrast Iodinated contrast agent formulations for radiographic imaging procedures.
• Telebrix Gastro Iodinated contrast agent for gastrointestinal imaging procedures.
• OptiOne CT contrast injection system for automated contrast delivery in computed tomography procedures.
• OptiVantage Multi-use Multi-patient CT contrast injection system designed for high-volume imaging centers.
• OptiVantage Single-use Single-use CT contrast injection system for improved hygiene and reduced cross-contamination risk.
• Illumena Neo Contrast injection solution for cardiac catheterization and hemodynamic imaging procedures.
• Lipiodol Ultra Fluid Iodinated ethyl esters of fatty acids of poppy seed oil. First iodinated contrast agent discovered worldwide (1901). Used primarily in interventional radiology for vascular embolization and in women's health. Available in 47 countries.
• Patent Blue V
• Qitexio Medical device for interventional radiology procedures.
• Vectorio Exclusive mixing and injection solution system for conventional trans-arterial chemoembolization (cTACE) consisting of Lipiodol-resistant medical device sets including syringes, patented stopcock, and sampling devices.
• SeQure Microcatheter Reflux-control microcatheter for flow-directed embolization in peripheral vessels. Features 2 radiopaque markers, reflux-prevention beads technology, and optimized flexibility for improved trackability. Delivers on average 3 times more embolic material to target vessel compared to standard microcatheters. Compatible with embolic microspheres 70-700 micrometers.
• DraKon Microcatheter Standard microcatheter adapted for peripheral embolization including cTACE. Features optimized pushability, flexibility, and torqueability for improved trackability. Compatible with Lipiodol Ultra Fluid, DMSO, chemotherapy agents, NBCA glue, and Ethanol. CE marked, available in US, Europe, Brazil and other countries.
• UNIK Diagnostic Imaging Interconnected Solutions
• icobrain
• Contrast & Care Digital contrast injection management solution for diagnostic imaging, enabling integrated workflow optimization and data management.
• DUOnco Pancreas AI software designed to support the reading of pancreatic areas on contrast-enhanced CT scans. Developed by Intrasense, a Guerbet Group subsidiary.
• OptiProtect 3S

Quantifiable outcome

• Elucirem (gadopiclenol) achieves effective MRI imaging at half the standard dose (0.05 mmol/kg vs 0.1 mmol/kg), reducing cumulative gadolinium exposure in patients requiring serial imaging
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Bracco ImagingcoreStrategic or Co-development Partner · 1 December 2021Guerbet and Bracco Imaging entered a worldwide collaboration agreement in December 2021 for gadopiclenol, a novel gadolinium-based contrast agent. Both companies share manufacturing responsibilities under separate commercial brands - Guerbet sells as Elucirem and Bracco as VUEWAY. The product achieves effective MRI imaging at half the standard dose with highest relaxivity. Health Canada approved VUEWAY in 2026, following US (2022) and EU (2023) approvals, with over 4 million patient doses administered worldwide.
• IntrasensecoreTechnology or Integration · 1 April 2019Guerbet acquired a stake in Intrasense and later announced its intent to file a voluntary tender offer, making it a subsidiary within the Guerbet Group. Intrasense specializes in AI medical imaging software including icobrain for radiology and DUOnco Pancreas for pancreatic cancer detection on CT. Intrasense received PMDA certification in Japan for DUOnco Pancreas AI software.
• IBM Watson HealthcoreStrategic or Co-development Partner · 1 January 2018Guerbet partnered with IBM Watson Health in 2018 for the co-development of AI-augmented solutions to help diagnose and treat liver cancer using CT and MRI imaging. A second contract was signed in 2019 for co-development of AI solutions for prostate cancer diagnosis and treatment. This is a strategic initiative to develop Guerbet's digital and AI business to improve radiologist productivity and tumor characterization through imaging.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Emerging players

• Aidoc: AI-powered radiology workflow company offering computer-aided detection across CT and MRI. Emerging competitor to Guerbet's Intrasense and IBM Watson Health AI diagnostic initiatives, focused on radiologist productivity and disease detection.
• icometrix: AI radiology company specializing in brain imaging quantification (icobrain), directly overlapping with Guerbet's Intrasense subsidiary offering icobrain software. Direct technology and use-case overlap in AI-augmented radiology workflows.

Direct peers

• Penumbra: US-based interventional radiology and vascular thrombectomy specialist with microcatheter and embolization technologies overlapping Guerbet's SeQure and DraKon microcatheter portfolio. Direct peer in the interventional radiology medical device segment.
• Bayer Radiology: Bayer's radiology business is a major global provider of iodinated contrast media (Ultravist, iohexol) and MRI contrast agents (Gadovist), serving the same hospital radiology departments as Guerbet. Direct overlap in product categories and customer base.
• Lantheus Holdings: US-based specialty radiopharmaceutical company offering contrast and diagnostic imaging agents (Definity, Xenon-133) for ultrasound and nuclear imaging. Comparable in scale and focus as a pure-play imaging diagnostics company competing in adjacent contrast and imaging agent categories.
• Bracco Imaging: Italian-headquartered global leader in diagnostic imaging and contrast agents, offering iodinated and gadolinium-based contrast media directly competitive with Guerbet's portfolio. Bracco is both a direct competitor across most contrast products and a co-commercialization partner on Gadopiclenol (VUEWAY brand), making it the closest peer.
• Daiichi Sankyo (Radiology): Japanese pharmaceutical major with a contrast media and diagnostic imaging business, competing globally with Guerbet in iodinated and gadolinium-based contrast agents. Particularly strong in Asia-Pacific markets where Guerbet also operates.

Broad incumbents

• GE Healthcare: GE Healthcare is a global incumbent across medical imaging equipment (CT, MRI, X-ray) and contrast media, including the historical Omnipaque and Visipaque iodinated contrast agents. Broader portfolio across hardware, software, and pharmaceuticals makes it a broad incumbent competitor to Guerbet's contrast and injector offerings.
• Medtronic: Global medical device leader with significant interventional radiology, embolization, and microcatheter offerings following the Covidien acquisition. Broad incumbent competing with Guerbet's interventional imaging segment across hospital accounts.
• Boston Scientific: Global medical device incumbent with a substantial interventional radiology and peripheral vascular embolization portfolio. Overlaps with Guerbet's interventional imaging device franchise (SeQure, DraKon, Vectorio) as part of a much broader device portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/guerbetgroup
• YouTubeyoutube.com/user/guerbetgroup
• LinkedInlinkedin.com/company/guerbet
• Instagraminstagram.com/guerbetgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Guerbet